Salt Lake City—Topical antibiotic therapy before and after intraocular bacterial challenge in rabbits could prevent Staphylococcus epidermidis endophthalmitis from developing.
ISTA Pharmaceuticals acquired from Senju Pharmaceuticals an exclusive North American license to an eye-drop formulation containing bepotastine, an investigational ophthalmic treatment for allergic conjunctivitis. This is ISTA Pharmaceuticals' first license for the ophthalmic allergy field.
Bausch & Lomb has licensed two technologies for ophthalmic use. The company and Talecris Biotherapeutics, Research Triangle Park, NC, will co-develop rPlasmin, a recombinant derivative of the human blood component plasmin, which may have potential for use in developing novel therapies for ocular conditions. The agreement extends the partnership announced in 2005, in which Bausch & Lomb licensed plasma-delivered plasmin from Talecris predecessor Bayer Biological Products.
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) before and after cataract surgery significantly lowers the incidence of cystoid macular edema (CME) and provides patients with better quality of vision. The results of three studies presented at the annual meeting of the American Society of Cataract and Refractive Surgery, San Francisco, bore out that finding.
Afyon, Turkey—A highly flexible posterior chamber Collamer lens may be problematic for some cataract surgery patients and require an exchange due to progressive hyperopia, explained Faruk Ozturk, MD.
Salt Lake City—Implantation of a hydrophilic acrylic IOL (C-flex, Rayner) presoaked in a solution containing a fourth-generation fluoroquinolone resulted in anterior aqueous humor concentrations of antibiotic that were significantly higher and more persistent than what was achieved with a topical drop administration protocol, according to the results of a preclinical study undertaken by Guy Kleinmann, MD, and colleagues at the John A. Moran Eye Center, University of Utah Health Science Center, Salt Lake City.
Durham, NC—A fluocinolone acetonide sustained drug delivery system (Retisert, Bausch & Lomb) implanted in patients with chronic macular edema associated with retinal venous occlusive disease reduced the edema and improved visual acuity in a significant portion of the eyes of 19 patients enrolled in the first 12 months of a 3-year study.
Talecris Biotherapeutics granted Bausch & Lomb the exclusive license to recombinant plasmin technology for use in ophthalmology. Bausch & Lomb and Talecris Biotherapeutics co-developed rPlasmin, a recombinant derivative of the human blood component plasmin. The enzyme degrades many blood plasma proteins, including fibrin clots.
An educational Breakfast Symposium
Dubai, United Arab Emirates—The use of topical peripheral annular application of mitomycin-C (MMC) 0.02% for 2 minutes is safe and effective in preventing corneal scarring after PRK with more predictable refractive outcomes. In addition, it decreases the potential for side effects, especially damage to the corneal endothelium, associated with topical MMC disc application and central corneal exposure to MMC, according to Elias F. Jarade, MD.